Oculis Holding AG (FRA:CR5) Pretax Margin %: % (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:CR5 Oculis Holding AG FRA:CR5
22 GF Score
Price €10.75
! 1 Warning Sign
View Full Analysis

What is Oculis Holding AG Pretax Margin %?

Oculis Holding AG FRA:CR5 -5.29% 22 Pretax Margin % is % as of Mar. 2026. GuruFocus rates FRA:CR5 with a GF Score™ of 22/100. The stock has 1 warning sign investors should review. Among 941 Biotechnology companies, Oculis Holding AG ranks worse than 106269.82% on this metric.

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Oculis Holding AG's Pre-Tax Income for the three months ended in Mar. 2026 was €-31.81 Mil. Oculis Holding AG's Revenue for the three months ended in Mar. 2026 was €0.00 Mil. Therefore, Oculis Holding AG's pretax margin for the quarter that ended in Mar. 2026 was %.

The historical rank and industry rank for Oculis Holding AG's Pretax Margin % or its related term are showing as below:


FRA:CR5's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -89.42
* Ranked among companies with meaningful Pretax Margin % only.

Oculis Holding AG  (FRA:CR5) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.

Oculis Holding AG Pretax Margin % Related Terms

Oculis Holding AG Pretax Margin % Historical Data

* Premium members only.

The historical data trend for Oculis Holding AG's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oculis Holding AG Pretax Margin % Chart

Oculis Holding AG Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Pretax Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Oculis Holding AG Quarterly Data
Dec20 Sep21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:CR5 vs NVCT, AURA, CADL: Pretax Margin % Comparison

For the Biotechnology subindustry, Oculis Holding AG's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oculis Holding AG Pretax Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oculis Holding AG's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Oculis Holding AG's Pretax Margin % falls into.


FRA:CR5
22GF Score
Oculis Holding AG FRA:CR5
Pretax Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oculis Holding AG Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Oculis Holding AG's Pretax Margin for the fiscal year that ended in Dec. 2025 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-106.247/0
= %

Oculis Holding AG's Pretax Margin for the quarter that ended in Mar. 2026 is calculated as

Pretax Margin=Pre-Tax Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-31.807/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Pretax Margin % →
What does a Pretax Margin % of % mean?
Oculis Holding AG (FRA:CR5) has a Pretax Margin % of % as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Oculis Holding AG and its competitors. According to the industry distribution chart, Oculis Holding AG ranks #999999 out of 941 companies in the Biotechnology industry.
Is Oculis Holding AG's Pretax Margin % too high?
Oculis Holding AG's current Pretax Margin % is %. Based on the distribution chart, Oculis Holding AG ranks #999999 out of 941 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Oculis Holding AG has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Oculis Holding AG's Pretax Margin % compare to NVCT and AURA?
According to the Biotechnology industry distribution chart, Oculis Holding AG ranks #999999 out of 941 companies for Pretax Margin %. This places Oculis Holding AG in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Oculis Holding AG and its competitors. Oculis Holding AG's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oculis Holding AG stock overvalued right now?
Oculis Holding AG (FRA:CR5) has a current Pretax Margin % of %. The current Pretax Margin % is %. Oculis Holding AG's overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Oculis Holding AG (FRA:CR5), the current Pretax Margin % is % as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oculis Holding AG Business Description

Address Bahnhofstrasse 20, Zug, CHE, CH-6300
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.
22GF Score

Get the complete analysis for FRA:CR5

Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€10.75
Price